New drug combo tested for tough cancers
NCT ID NCT05025085
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 33 times
Summary
This early-phase study tested a new drug called AGEN1777, given alone or with another cancer drug (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. This is a first step to see if the approach is worth studying further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Local Institution - 0001
Providence, Rhode Island, 02903, United States
-
Local Institution - 024
Southfield, Michigan, 48075, United States
-
Local Institution - 072
Cincinnati, Ohio, 45267-0558, United States
-
Local Institution - 164
Dallas, Texas, 75230, United States
-
Local Institution - 165
Grand Rapids, Michigan, 49546, United States
-
MD Anderson Cancer Center Thoracic-Head & Neck Med Onc
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Providence Cancer Institute
Portland, Oregon, 97213, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
University of Cincinnati Cancer Center
Cincinnati, Ohio, 45267, United States
Conditions
Explore the condition pages connected to this study.